The recent interim analysis of the Phase III TULIP-SC trial demonstrates SAPHNELO’s potential to significantly reduce disease activity in systemic lupus erythematosus patients, marking a pivotal advancement in treatment options. This positive outcome not only reinforces SAPHNELO’s established safety profile but also positions AstraZeneca as a key player in addressing this complex autoimmune condition.
WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca’s SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.1 The safety profile observed in the interim analysis was consistent with the known clinical profile of SAP
Source: Original Press Release
